JBIO biotech catalysts & pipeline

JADE BIOSCIENCES INC · Data as of 2026-10-25

Upcoming catalysts

JADE201 — Interim data

2027

Announced dosing began in the Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis; interim, biomarker-rich data expected in 2027 are anticipated to inform indication prioritization and a focused clinical development strategy.

Source filing

JADE101 — Interim data

Q2 2027

JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027

Source filing

JADE301 — Interim data

H2 2027

Jade expects to initiate a placebo-controlled, single ascending-dose Phase 1 trial evaluating subcutaneous JADE301 in 24 healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar